Loading...
•
Jun 30, 2022
Kiniksa Q2 2022 Earnings Report
Kiniksa's financial performance in Q2 2022 showed ARCALYST's continued momentum and strategic portfolio expansion.
Key Takeaways
Kiniksa Pharmaceuticals reported ARCALYST net revenue of $27.0 million for Q2 2022. The company anticipates $100 million in upfront and near-term proceeds from the vixarelimab global license agreement and expects cash reserves to fund operations into at least 2025.
ARCALYST net revenue reached $27.0 million in Q2 2022.
Full-year 2022 net revenue for ARCALYST is expected to be $115 - $130 million.
The vixarelimab global license agreement is expected to generate $100 million in upfront and near-term proceeds.
Cash reserves are projected to fund operations into at least 2025 following the vixarelimab agreement.
Revenue by Segment
Forward Guidance
Kiniksa expects ARCALYST net revenue for full-year 2022 to be between $115 million and $130 million. The company plans to evolve its sales operation with approximately 20 additional field sales representatives in the fourth quarter of 2022.
Positive Outlook
- ARCALYST net revenue for full-year 2022 expected to be between $115 million and $130 million
- Cash reserves expected to fund operations into at least 2025 following the close of the vixarelimab global license agreement with Genentech
- Plans to evolve sales operation with approximately 20 additional field sales representatives in the fourth quarter of 2022
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...